As part of the collaboration, LabCorp has also made an equity investment into MC10. The companies’ collaboration will support the adoption of MC10’s proprietary technology for use by LabCorp’s Covance Drug Development business in clinical trials and research studies, with the potential to be adapted over time for use in patient testing and monitoring.

“Our collaboration with LabCorp focusing first on Covance, will accelerate the delivery of MC10’s innovative digital health solutions to our shared customer base in the pharmaceutical industry. We are optimistic for the growing portfolio of projects that will leverage LabCorp’s differentiated diagnostic expertise and MC10’s medical-grade wearable systems to advance our mission of reshaping healthcare with digital solutions,” commented Ben Schlatka, Co-Founder and Senior Vice President of Corporate Development at MC10. To launch the collaboration, Covance is supporting the adoption of the BioStamp system in research studies best suited for mobile monitoring of participating subjects.

“We are confident that our collaboration with the great team at MC10 will help to bring new medicines to patients faster, advancing our mission to improve health and improve lives.”

About MC10, Inc.MC10 is a private company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions.

MC10 has received widespread recognition for its revolutionary technology and was recently named in Fast Company’s Most Innovative Companies in 2016 as a leader in healthcare.